

II. Amendments to the Claims

The following listing of claims replaces all prior versions, and listings, of claims in the application:

1. (Canceled)
2. (Previously Presented) A method according to claim 29, wherein said delivering comprises:
 - providing an occlusive body which comprises the cannabinoid; and
 - positioning the occlusive body on the subject's skin under conditions effective to transdermally deliver the selected cannabinoid to the subject's skin.
3. (Previously Presented) A method according to claim 2, wherein the occlusive body further comprises:
 - an impermeable backing; and
 - a rate-controlling microporous membrane, wherein the backing and membrane define a cavity therebetween and wherein the selected cannabinoid is disposed within the cavity.
4. (Original) A method according to claim 3, wherein the selected occlusive body further comprises:
 - a viscous flowable gel disposed within the cavity, wherein the viscous flowable gel immobilizes the cannabinoid within the cavity.

5. (Original) A method according to claim 3, wherein the occlusive body further comprises:
an adhesive for attaching the occlusive body to skin.

6. (Previously Presented) A method according to claim 29, wherein the illness is selected from
the group consisting of AIDS and cancer.

7. (Canceled)

8. (Previously Presented) A method according to claim 29, wherein the selected cannabinoid is
delivered via a topical formulation.

9. (Previously Presented) A method according to claim 29, wherein the selected cannabinoid is
delivered via a patch.

10. (Previously Presented) A method according to claim 29, further comprising the steps of:
providing an opiate; and
delivering the opiate transdermally with the cannabinoid to the subject.

11-28. (Canceled)

29. (Previously Presented) A method for relieving symptoms associated with illness or
discomfort associated with the treatment of illness in a mammalian subject, said method

comprising:

providing a cannabinoid composition consisting essentially of cannabidiol; and
delivering the cannabinoid composition transdermally to the subject.

30. (Previously Presented) The method of claim 29 wherein the subject is selected from the group consisting of patients experiencing a loss of appetite, patients experiencing chronic pain, patients experiencing spasticity, patients experiencing dystonia, and patients experiencing nausea and vomiting.